공시 • May 29
PROCEPT Biorobotics® Advances Prostate Cancer Program With WATER IV Study Enrollment Completion And Expanded IDE Approval PROCEPT BioRobotics announced two milestones in its WATER IV prostate cancer clinical program: completion of enrollment in the randomized WATER IV study evaluating Aquablation therapy versus radical prostatectomy, and FDA Investigational Device Exemption (IDE) approval for a second randomized protocol evaluating Aquablation therapy versus active surveillance. The first randomized WATER IV study (WATER IV RP) fully enrolled 280 planned patients and is the only FDA randomized study comparing Aquablation therapy to radical prostatectomy, the established surgical standard of care. Based on current timelines, the Company expects to present the WATER IV RP primary endpoint results at the American Urological Association (AUA) Annual Meeting in spring 2027. The second randomized study in the WATER IV clinical program (WATER IV AS) will enroll up to 333 patients globally and evaluate Aquablation therapy versus active surveillance in men with Grade Group 1 and 2 prostate cancer. WATER IV AS is designed to evaluate whether Aquablation therapy may provide an earlier treatment option for men on active surveillance before the disease progresses further. Patients will be followed for ten years, including biopsy assessment at one year and MRI-based whole gland evaluation at three years. Both randomized WATER IV protocols will follow patients for ten years and are designed to evaluate the long-term experience of men with prostate cancer. The studies will assess both disease control and quality-of-life outcomes over time, including the impact of treatment on urinary, sexual, and overall function. Ultrasound-guided, transurethral robotic waterjet resection of the prostate is designed to remove cancer, at-risk tissue, and any obstructive tissue resulting in more than 95% of the gland being resected leaving only the outer prostatic capsule intact. 공시 • Apr 23
PROCEPT BioRobotics Corporation, Annual General Meeting, Jun 09, 2026 PROCEPT BioRobotics Corporation, Annual General Meeting, Jun 09, 2026. Location: htps:/meetnow.global/mr7c96h, United States 공시 • Apr 10
PROCEPT BioRobotics Corporation to Report Q1, 2026 Results on Apr 29, 2026 PROCEPT BioRobotics Corporation announced that they will report Q1, 2026 results After-Market on Apr 29, 2026 공시 • Mar 23
PROCEPT BioRobotics Highlights Upgrade of Aquablation Therapy in European Association of Urology Guidelines PROCEPT BioRobotics highlighted the latest update to the European Association of Urology Guidelines for male lower urinary tract symptoms, which include an upgrade of Aquablation therapy to a strong recommendation as a surgical treatment option for men with benign prostatic hyperplasia. The updated guidelines now strongly recommend offering Aquablation therapy as an alternative to transurethral resection of the prostate for men with moderate-to-severe urinary symptoms due to benign prostatic hyperplasia, particularly for patients interested in preserving ejaculatory function. Guidelines are supported by outcomes from multiple clinical trials on Aquablation therapy, including WATER, a randomized trial against transurethral resection of the prostate, and WATER II trials demonstrating durable improvements in urinary symptoms and preservation of sexual and urinary function. The guidelines also now recognize evidence supporting Aquablation therapy across a broad range of prostate anatomies, including larger prostate glands, with additional evidence continuing to emerge from recently published studies such as WATER III, a randomized trial against laser enucleation in large glands. Recognition from the European Association of Urology adds to growing international clinical validation for Aquablation therapy, including support from health technology assessment bodies such as the National Institute for Health and Care Excellence in the United Kingdom supporting the routine use of Aquablation therapy within the NHS. PROCEPT BioRobotics manufactures the AQUABEAM and HYDROS Robotic Systems. The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia that are independent of prostate size and shape or surgeon experience. PROCEPT BioRobotics has developed a significant and growing body of clinical evidence with approximately 250 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy. All surgical treatments have inherent and associated side effects. 공시 • Mar 13
Procept Biorobotics Announces International Launch of the Hydros Robotic System, Expanding Global Access to Ai-Enabled Aquablation Therapy PROCEPT BioRobotics announced the international expansion of the HYDROS Robotic System, the company’s next-generation platform for delivering Aquablation therapy to treat benign prostatic hyperplasia (BPH). HYDROS is the first AI-enabled robotic platform designed specifically for the treatment of BPH with Aquablation therapy. Leveraging AI-interpreted, real-time ultrasound imaging and advanced image-guided treatment planning, the system enables surgeons to deliver personalized, anatomy-specific therapy with robotic precision and reproducibility. The platform is designed to support scalable adoption across care settings while maintaining consistent procedural execution. Aquablation therapy offers a complete solution for men living with BPH. A robust body of clinical evidence continues to demonstrate Aquablation delivers durable symptom relief while preserving sexual and urinary function, outcomes that are critically important to patients. The HYDROS Robotic System brings AI-enabled, real-time ultrasound-guidance and robotic assisted treatment planning to NICE-recommended Aquablation therapy in the UK, supporting precise, anatomy-specific treatment. Aquablation with HYDROS enables durable symptom relief and preservation of quality-of-life outcomes, including sexual and urinary function and meaningfully expands surgical choice for men living with BPH. Aquablation therapy is the first and only ultrasound guided, robotic-assisted, heat-free waterjet for the treatment of BPH. The system’s real-time ultrasound imaging provides the surgeon with a multi-dimensional view of the prostate enabling personalized treatment planning tailored to each patient’s unique anatomy. The surgeon can specify which areas of the prostate to remove while preserving the anatomy that controls erectile function, ejaculatory function and continence. Once the treatment plan is mapped by the surgeon, the predictable robotic-assisted execution enables prostate tissue to be removed in a precise, targeted and controlled fashion. All surgical treatments have inherent and associated side effects. 공시 • Mar 06
Procept Biorobotics Corporation Appoints Daniel Puckett Board and Audit Committee Member, Effective March 5, 2026 On March 5, 2026, the board of directors (the “Board”) of PROCEPT BioRobotics Corporation (the “Company”) approved (i) an increase in the size of the Board from eight members to nine members, (ii) appointed Mr. Daniel Puckett as a new member of the Board to fill the resulting vacancy, and (iii) appointed Mr. Puckett as a member of the Audit Committee of the Board, with such appointment effective immediately. Mr. Puckett was classified as a Class III director, and his initial term will expire at the Company’s 2027 annual meeting of stockholders and until his successor has been elected and qualified, or until his earlier death, resignation or removal. The Board has determined that Mr. Puckett is an “independent director” as defined under the applicable rules and regulations of the Securities and Exchange Commission (“SEC”) and the listing requirements and rules of the Nasdaq stock market, and, accordingly, determined he is qualified to serve on the Audit Committee of the Board. Mr. Puckett previously served as Chief Financial Officer of Shockwave Medical Inc., a leading medical device company that develops treatments for cardiovascular disease, from April 2016 until his retirement in February 2024. Prior to Shockwave Medical, he served as Chief Financial Officer of Counsyl Inc., from June 2015 to April 2016 and as Chief Financial Officer of Ariosa Diagnostics Inc. from 2011 to June 2015. Earlier in his career, Mr. Puckett held senior finance and operations roles at Forest Laboratories Inc. and its subsidiary Cerexa Inc., as well as at Affymetrix Inc. and AOL Inc. He received an M.B.A. from the University of San Francisco and a B.A. in Accounting from Washington State University. 
